Vivian Moura Oliveira

Prof. Dr. Vivian Moura Oliveira

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
VOVivian Moura Oliveira
Vivian Moura Oliveira
MCMatheus Rezende Corrêa
Matheus Rezende Corrêa
ISIsabela Cristina Vieira Silva
Isabela Cristina Vieira Silva
LCLarissa Rezende Corrêa
Larissa Rezende Corrêa
MGMaria Gomes
Maria Gomes
Entamoeba histolytica is the cause of amoebiasis, a neglected tropical disease and a leading cause of mortality worldwide. The objective of this review is to show the potential of probiotics as a treatment strategy for amoebiasis. A systematic search was conducted using PubMed and Google Scholar with keywords "Entamoeba histolytica", "amoebiasis", and "probiotics." The studies on probiotics for amoebiasis treatment are limited, but some shown promising results. Lactobacillus acidophilus reduced E. histolytica cyst excretion by 79.67% in mice, with a 68.31% efficacy comparable to metronidazole. Bifidobacterium sp. showed 75.63% efficacy in reducing infection severity, higher than metronidazole (67.56%). Lactobacillus salivarius inhibited E. histolytica growth in vitro and provided protection in vivo. Lactobacillus fermentum and L. delbrueckii inhibited E. histolytica proliferation with efficacy ranging from 46.42% to 97.68%, depending on the concentration. Saccharomyces boulardii reduced amoebic dysentery duration by 25% and eliminated parasitic cysts in human stool samples. Lactobacillus casei showed a 100% recovery rate in rats infected with E. histolytica. These findings suggest probiotics have potential as therapeutic agents for amoebiasis, but further research is needed to confirm their effectiveness in animal models and humans.

1 January 2026 in Anais da Academia Brasileira de Ciências
Verified
Journal Article
Open access
DODirce R. DE Oliveira
Dirce R. DE Oliveira
MAMichelle B.M.P. Antunes
Michelle B.M.P. Antunes
VOVivian Moura Oliveira
Vivian Moura Oliveira
RCRuth E. Cruz
Ruth E. Cruz
MGMaria Gomes
Maria Gomes
Giardia lamblia infection alters gut physiology and microbiota interactions, but the impact of prebiotic supplementation in this context remains unclear. This study investigated how fructooligosaccharide (FOS) treatment affects microbial fermentation, intestinal function, inflammation, and hepatic bile acid synthesis in G. lamblia-infected gerbils. Gerbils were divided into four groups: uninfected control, infected control, uninfected and FOS-treated, and infected and FOS-treated. Cecal short-chain fatty acids (SCFAs), intestinal disaccharidase activities, serum and intestinal cytokines, and hepatic expression of Cyp7a1 and Cyp8b1 were analysed. Giardia infection increased cecal acetate, reduced butyrate, elevated serum TNF-α, and increased hepatic Cyp7a1 expression. FOS supplementation increased cecal propionate and other SCFAs and elevated IL-10 levels in serum and intestinal tissue. Notably, FOS reduced intestinal maltase activity regardless of infection status, without affecting lactase activity. Together, these data indicate that giardiasis alters microbial fermentation and inflammatory responses, whereas FOS supplementation primarily promotes a more regulatory immune profile, characterized by increased IL-10 levels, alongside shifts in microbial fermentation, without directly modifying hepatic bile acid–related gene expression. These findings highlight complex diet–microbiota–host interactions during intestinal parasitic infection and support further mechanistic studies.

5 April 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
VOVivian Moura Oliveira
Vivian Moura Oliveira
FOFabrício Marcus Silva Oliveira
Fabrício Marcus Silva Oliveira
OMOlga L. M. Moreno
Olga L. M. Moreno
JFJulia R. Ferreira
Julia R. Ferreira
RSRaphael Szawka
Raphael Szawka
MGMaria Gomes
Maria Gomes
Amebiasis is a globally prevalent infection that can lead to fatal outcomes if not adequately treated. Conventional treatment with imidazoles often fails due to side effects and resistance, emphasizing the need for alternative therapies. The probiotic Escherichia coli Nissle 1917 (EcN) has shown potential in combating intestinal pathogens. This study aimed to evaluate the amebicidal activity of EcN in vitro and its effect on the production of reactive oxygen species (ROS). Trophozoites of Entamoeba histolytica (2.5 × 10⁴ cells/mL) were cultured in 96-well plates and exposed to varying concentrations of EcN (102–109 cells/mL). Plates were incubated at 36 °C for 6, 12, and 18 h, after which trophozoite viability was assessed. Intracellular ROS production, including superoxide and hydrogen peroxide, was measured using fluorescent probes. The highest efficacy was observed after 18 h at a CFU concentration of 109 cells/mL. Increased ROS production at all probiotic concentrations suggested a role in EcN’s amebicidal mechanism. Morphological changes in trophozoites, such as rounding, vacuolization, and size reduction, were noted after EcN exposure, indicating growth inhibition. These findings suggest EcN induces structural and morphological changes in E. histolytica, inhibiting its growth in vitro. The findings suggest the potential efficacy of EcN; however, definitive confirmation requires data from human clinical trials.